x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

POMALYST® (pomalidomide) nurse resources.

What is RRMM?

More likely than not, this is a question you’ve heard before. RRMM is defined as MM that has become nonresponsive or progressive on therapy, or within 60 days of the last treatment, in patients who had achieved a minimal response (MR) or better on prior therapy.1 Help your patients understand what RRMM is and ensure that they know there are therapies approved specifically for RRMM.

POMALYST® (pomalidomide) Patient Website Icon for Patients

For a patient-friendly explanation of what RRMM is and additional resources, visit the patient website.

POMALYST® (pomalidomide) Patient Website Icon for Patients

For a patient-friendly explanation of what RRMM is and additional resources, visit the patient website.


Straightforward dosing, based on renal impairment.2

POMALYST® (pomalidomide) Renal Dosing – Recommended Dosage of Pomalyst Based on Renal Function

Capsules shown are not actual size. 1 cycle = 28 days.

POMALYST can be taken at home or wherever is convenient for your patient.2

  • Recommended dosage for POMALYST is 4 mg once daily orally with or without food on Days 1-21 of each 28-day cycle
  • Give POMALYST in combination with dex
  • In the doublet Phase 3 trial, low-dose dex was given on Days 1, 8, 15, and 22 of a 28-day cycle
    • Dex 40 mg for patients ≤75 years
    • Dex 20 mg for patients >75 years
  • Repeat until disease progression or unacceptable toxicity. Dose interruptions and modifications may be required

Tailor the POMALYST dosage to your patients’ needs.2

POMALYST® (pomalidomide) 4mg, 3mg, 2mg, 1mg Capsule Dosage Strengths
  • The recommended starting dose of POMALYST is 4 mg.
  • Additional strengths of 3 mg, 2 mg, and 1 mg are available for dose modification.

Dose modifications may help patients stay on therapy.

POMALYST® (pomalidomide) Thrombocytopenia Dose Modification Chart

*Permanently discontinue POMALYST if unable to tolerate 1 mg once daily.

  • To initiate a new cycle of POMALYST, the platelet count must be at least 50,000 per mcL2

In MM-003, thrombocytopenia of any grade was reported in 30% of patients treated with POMALYST + low-dose dex vs 29% treated with high-dose dex.2†

POMALYST + low-dose dex, n=300; high-dose dex, n=150.

POMALYST® (pomalidomide) Neutropenia Dose Modification Chart

*Permanently discontinue POMALYST if unable to tolerate 1 mg once daily.

Fever greater than or equal to 38.5 °C and ANC less than 1000 per mcL.

  • To initiate a new cycle of POMALYST, the neutrophil count must be at least 500 per mcL2

In MM-003, neutropenia of any grade was reported in 51% of patients treated with POMALYST + low-dose dex vs 21% treated with high-dose dex.2†

Important Dosing Information

  • POMALYST may be taken with or without food. Inform patients not to break, chew or open the capsules. Swallow capsules whole with water.
  • Monitor CBCs every week for the first 8 weeks and monthly thereafter. Patients may require dose interruption and/or modification.
  • Monitor liver function tests monthly. Stop POMALYST upon elevation of liver enzymes and evaluate. After return to baseline values, treatment at a lower dose may be considered.
  • Reduce POMALYST dose to 3 mg orally daily in patients with mild to moderate hepatic impairment and to 2 mg in patients with severe hepatic impairment.
  • Avoid concomitant use of POMALYST with strong inhibitors of CYP1A2. If concomitant use of a strong CYP1A2 inhibitor is unavoidable, reduce POMALYST dose to 2 mg.
  • Reduce POMALYST dose to 3 mg orally daily in patients with severe renal impairment requiring dialysis. Take dose of POMALYST following hemodialysis on hemodialysis days.

Permanently discontinue POMALYST for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reaction.

For other Grade 3 or 4 toxicities2:

  • Hold treatment. Restart treatment at 1 mg less than the previous dose when the toxicity has resolved to less than or equal to Grade 2 at the physician’s discretion.

POMALYST + low-dose dex, n=300; high-dose dex, n=150.

POMALYST patient case: managing thrombocytopenia

Female POMALYST® (pomalidomide) Patient

Learn how dose modification can help keep a patient with thrombocytopenia on treatment.


Now Is the Time for a Different IMiD®

NCCN Recommendations Chart NCCN Recommendations Chart

Information about DPd does not appear in the POMALYST Prescribing Information (PI). Please see the daratumumab full PI for a complete discussion of Important Safety Information at


  • Daratumumab is contraindicated in patients with a history of severe hypersensitivity (e.g., anaphylactic reactions) to daratumumab or any of the components of the formulation.

Daratumumab is associated with the following Warnings and Precautions: Infusion-Related Reactions, Interference With Cross-Matching and Red Blood Cell Antibody Screening, Neutropenia, Thrombocytopenia, Interference With Determination of Complete Response, and Embryo-Fetal Toxicity.

Starting patients on POMALYST


Embryo-Fetal Toxicity

POMALYST is a thalidomide analogue and is contraindicated for use during pregnancy. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. POMALYST is only available through the POMALYST REMS program.

Females of Reproductive Potential

Females of reproductive potential must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy.

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy.

Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing POMALYST therapy; and then weekly during the first month, then monthly thereafter in females with regular menstrual cycles, or every 2 weeks in females with irregular menstrual cycles.


Pomalidomide is present in the semen of patients receiving the drug. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 4 weeks after discontinuing POMALYST, even if they have undergone a successful vasectomy. Male patients taking POMALYST must not donate sperm.

Blood Donation

Patients must not donate blood during treatment with POMALYST and for 4 weeks following discontinuation of POMALYST therapy because the blood might be given to a pregnant female patient whose fetus must not be exposed to POMALYST.

Patient Access, Reimbursement, and Co-Pay Support

Available Through

Bristol Myers SquibbTM Access Support® Site

Bristol Myers Squibb is committed to helping appropriate patients initiate and maintain access to our medications during the treatment journey. That’s why we created BMS Access Support®, which offers benefit review, prior authorization assistance, and appeal process support, as well as an easy-to-initiate co-pay assistance process and information on financial support. The BMS Access Support Co-pay Assistance Program assists with out-of-pocket co-payment or co-insurance requirements for eligible, commercially insured patients who have been prescribed certain Bristol-Myers Squibb products, including POMALYST. For more information, visit BMS Access Support, or call BMS Access Support at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday.

Additional POMALYST resources and tools for patients and caregivers


Getting My Medication Brochure

Getting My Medication

A brochure patients can use to make sure they receive their medication.

POMALYST® (pomalidomide) Medication Guide

Medication Guide

Contains FDA-approved information that can help patients learn about POMALYST.

POMALYST® (pomalidomide) Treatment Overview Brochure

My Disease & Treatment

This brochure can help patients learn about their disease, treatment, and how to get ongoing support.

Caregiver Brochure

Taking Care

A caregiver’s guide to supporting someone with multiple myeloma.

Conversation Starter Brochure

Conversation Starter

Questions a patient or caregiver can ask to help them talk with healthcare providers about multiple myeloma and disease treatment.

REMS Companion App Icon

REMS Companion App

An overview of the REMS Companion App and instructions on how to download, log in, and use the app.



POMALYST® (pomalidomide) FAQ Icon

Frequently Asked Questions     

POMALYST® (pomalidomide) Patient & Caregiver Organizations Icon

Patient & Caregiver Organizations

Learn More
Specialty Pharmacy Network Icon

Specialty Pharmacy Network

Learn More

ANC, absolute neutrophil count; CBC, complete blood count; D/dara, daratumumab; dara SC, daratumumab and hyaluronidase-fihj subcutaneous; d/dex, dexamethasone; EPd, POMALYST + dexamethasone + EMPLICITI® (elotuzumab); FDA, U.S. Food and Drug Administration; IsaPd, POMALYST + dexamethasone + isatuximab-irfc; IV, intravenous; LoT, lines of therapy; MM, multiple myeloma; MR, minimal response; PI, proteasome inhibitor; RRMM, relapsed/refractory multiple myeloma.

References: 1. Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396-406. 2. POMALYST [package insert]. Summit, NJ: Celgene Corp. 3. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol. 2013;14(11)1055-1066. 4. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc. 5. Daratumumab and hyaluronidase-fihj [package insert]. Horsham, PA: Janssen Biotech, Inc. 6. Bahlis NJ, Siegel D, Schiller G, et al. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leuk Lymphoma. 2022 Feb 8;1-11. 7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed December 8, 2022. To view the most recent and complete version of the guidelines, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 8. Bristol-Myers Squibb Co; January 2023.

Share helpful tools and resources
for your patients.

View Patient Resources